From Lancaster General Health, Lancaster, Pennsylvania
|
|
- Jasper Tate
- 6 years ago
- Views:
Transcription
1 Prothrombin Complex Concentrate Accelerates International Normalized Ratio Reversal and Diminishes the Extension of Intracranial Hemorrhage in Geriatric Trauma Patients MATHEW EDAVETTAL, M.D., PH.D., AMELIA ROGERS, B.S., FREDERICK ROGERS, M.D., MICHAEL HORST, PH.D., WICHITAH LENG, PHARM.D From Lancaster General Health, Lancaster, Pennsylvania Warfarin therapy increases the incidence intracranial hemorrhage (ICH), especially in the geriatric population. Timely reversal of international normalized ratio (INR) is integral in the management of these patients for whom fresh frozen plasma (FFP) with vitamin K is the standard of treatment. We hypothesized that implementing a protocol that used prothrombin complex concentrate (PCC) would reverse INR values more swiftly and decrease the amount of FFP administered. In November 2011, a protocol was implemented for administering PCC to the geriatric population on warfarin admitted for life-threatening bleeds. These patients received 25 IU/kg ideal body weight of a three-factor PCC (Profilnine SD) if their INR was over 1.5 or greater. FFP was given if follow-up INR revealed an INR of 1.5 or greater. Retrospectively the data from 29 patients who received PCC were compared with a historical control group of 34 patients. Protocol use resulted in a significantly faster INR reversal (PCC: minutes vs control: minutes; P \ 0.001), time to achieve an INR less than 1.5 (PCC: minutes vs control: minutes; P ), and less FFP administered (PCC: vs control: ; P \ 0.001). PCC patients had a decreased incidence of progression of their ICH (PCC: 17.2% vs control: 44.2%; P ). Rapid reversal of coagulopathy in geriatric patients on warfarin is vital to limit the extent of ICH. PCC allows a much more rapid reversal than standard treatment with only FFP and vitamin K. Adopting such a protocol is associated not only with a more rapid reversal and less FFP use, but also less patients went on to extend their head bleeds. T HE GERIATRIC POPULATION represents one of the fastest growing segments of our society. The 2010 U.S. Census data note that adults older than 65 years now comprise 13 per cent of U.S. residents. 1 Many of these patients represent a significant healthcare burden when they get injured because of comorbid conditions. A significant proportion of these patients are on oral anticoagulant therapy (OAT) such as warfarin because of comorbidities such as atrial fibrillation, history of deep vein thrombosis, pulmonary embolism, or prophylaxis after prosthetic valve replacement. When these patients are injured, they can be vexing management problems for trauma surgeons because of their tendency to bleed, especially if they sustain head Presented at the 2012 Annual Assembly of the American Association for the Surgery of Trauma, Kauai, HI, September Address correspondence and reprint requests to Mathew Edavettal, M.D., Ph.D., 555 N. Duke Street, Lancaster, PA medavettal2@lghealth.org. injuries. There are numerous studies that attest to the fact that preinjury OAT worsens outcome after head injury. 2 7 Furthermore, it has been shown that the rapidity of reversal of OAT can improve mortality. 7 9 The mainstay of OAT reversal involves vitamin K and/ or fresh-frozen plasma (FFP). Although vitamin K is highly efficacious in reversing warfarin induced coagulopathy, peak effect may take up to 24 hours. 10, 11 FFP can work faster, but still requires time for type and cross, thawing, and administration. 12, 13 Both FFP and vitamin K are time-dependent reversal agents in which one is dealing with a threatening intracranial bleed. Prothrombin complex concentrate (PCC) is a concentrate vitamin K-dependent coagulation factor that was first used to treat hemophilia. 14 PCC confers an advantage over vitamin K and FFP in the reversal of OAT in that it does not require type and cross and thawing. Most of the research that has been done on reversal of OAT has been conducted in Europe and has used four factor PCC In the United States, 372
2 No. 4 PCC VS. FFP IN ICH FOR WARFARIN REVERSAL? Edavettal et al. 373 there had only been three-factor PCC (Profilnine SD and Bebulin VH) available until May 2013 when four-factor PCC became available. Presently, very little research has been published pertaining to the efficacy of three-factor PCC. Chong et al. 19 concluded that three-factor PCC prevented intracranial hematoma (ICH) expansion and was able to quicken neurosurgical intervention in patients of all ages. Cabral et al. 20 showed rapid reversal of elevated international normalized ratio (INR) in patients with ICH, but their median initial INR was 2.3. Switzer et al. 21 showed partial efficacy of high-dose, three-factor PCC in reversing an increased INR in patients with ICH; however, this study had a high complication rate, including pulmonary embolism, ischemic strokes, and venous thrombosis. None of the studies included a control group or examined primarily geriatric patients We had noted at our Level II trauma center that several patients had progression of their intracranial bleeds with deleterious outcomes while undergoing OAT reversal with FFP and vitamin K. We petitioned our Pharmacy and Therapeutics Committee to place PCC on formulary for the rapid reversal of OAT in patients with an intracranial bleed using a strict protocol and assiduous performance improvement. We hypothesized that a PCC protocol would decrease the time for OAT reversal, decrease the use of FFP, and halt the extension of ICHs of elderly patients on OAT after head injury. Methods The trauma service at Lancaster General Hospital is a mature, Level II trauma center verified by the Pennsylvania Trauma Systems Foundation since Approval by the Institutional Review Board of Lancaster General Health has been received for this study. In November 2011, our institution implemented a policy for administering PCC in the geriatric population (age 65 years or older) sustaining life-threatening bleeding for the reversal of warfarin-induced coagulopathy (Fig. 1). Coagulopathy was defined as an INR of 1.5 or greater. Profilnine SD (Grifols Biologicals Inc., Los Angeles, CA), a three-factor PCC obtained from pooled human plasma; viral inactivation is conducted by solvent detergent. 22 The factor composition is 100 to 150 IU/mL factor IX, 1.5 IU or less factor II per 1 IU factor IX, 1 IU or less factor X per 1 IU factor IX, and 0.35 IU or less factor VII per 1 IU Factor IX. 15 Profilnine SD does not contain any heparin. 22 If the initial INR is 1.5 or greater, then patients were given 25 IU/kg PCC (Profilnine SD) of ideal body weight along with 10 mg vitamin K intravenously over 30 minutes. A half hour after PCC administration, patients had a follow-up INR check. If the repeat INR was not 1.5 or less, then patients were given FFP. We retrospectively examined patients who received PCC and compared them with a historical control group of patients (control) obtained from our trauma registry ( Collector ; Digital Innovations, Forest Hills, FIG. 1. Post-PCC implementation: anticoagulant reversal management guideline.
3 374 THE AMERICAN SURGEON April 2014 Vol. 80 MD). The control group consisted of all patients admitted to the trauma service from November 2010 into November 2011 who were 65 years of age or older on prehospital warfarin with a head injury of Abbreviated Injury Score (AIS) 2 or greater and reversed with only vitamin K and FFP (Fig. 2). Patients included in the PCC group were 65 years of age or older, on prehospital warfarin, with a head injury of AIS 2 or greater and reversed with PCC and vitamin K. Patients were excluded from either group if they were given factor VII, had an initial INR 1.0 or less, or had a pre-existing thrombus, for which PCC was contraindicated. We collected age, gender, trauma activation level, initial INR, follow-up INR, time for INR to decrease to less than 1.5, amount of FFP given, time in minutes between the first head computed tomography (CT) scan and when PCC or FFP was first given, time in minutes between the first INR and second INR, admission Glasgow Coma Scale (GCS), discharge GCS, if neurosurgical intervention occurred, intensive care unit days, hospital length of stay, Injury Severity Score (ISS), AIS for the head, if the bleed increased on followup head CT scan, and mortality during hospital admission (Table 1). A bleed was considered to be extended based on the radiologist s impression of the follow-up head CT scan. The PCC group was compared with the FFP group using Student s t test for continuous variables and Fisher s exact test for discontinuous variables. A P value < 0.05 was considered significant. Results There were 29 patients in the PCC group and 34 patients in the historical control group; two patients were dropped from the control group for incomplete data. Care was withdrawn within the first hour of arriving at the hospital on one patient, who was subsequently removed from the PCC group. The PCC group is comparable to the control group in their mean initial INRs (PCC 3.9 ± 1.6 vs control 3.4 ± 2.1; P ; Table 1), mean ISS (PCC 16 ± 8.0 vs control 18.4 ± 7.4; P ), mean AIS head score (PCC 3.6 ± 1.2 vs control 3.9 ± 0.95; P ) as well as the mean second INR (PCC 1.66 ± 0.26 vs control 1.70 ± 0.63; P ). However, there was a significant decrease in the time between initial INR and second INR in the PCC group compared with the control group (PCC 164 ± 90.7 minutes vs control 412 ± 381 minutes; P ; Table 1). Also, the amount of time in minutes to achieve an INR of less than 1.5 was significantly lower in the PCC group (PCC 489 ± 294 minutes vs control 959 ± 1192 minutes; P ; Table 1). There was a significant decrease in the mean amount of FFP given the PCC group (PCC 0.86 ± 1.1 units vs control 3.32 ± 1.5 units; P < 0.001). In addition, the PCC group saw a significant decrease in the number of patients who had an extension of their ICH as seen on repeat CT scan (17.2% PCC vs 44.2% control; P ; Table 1). We also observed a decrease in the rate of mortality (6.9% PCC vs 14.7% control) and need for FIG. 2. Pre-PCC implementation: anticoagulant reversal management guideline.
4 No. 4 PCC VS. FFP IN ICH FOR WARFARIN REVERSAL? Edavettal et al. 375 TABLE 1. Differences in Outcomes of PCC versus FFP Groups Case: PCC + FFP Control: FFP Only P Value No. 29 (46.03%) 34 (53.97%) Female 44.1% 48.3% Mean age (SD) (8.88) (12.76) Mean ISS 16 (8.02) (7.40) Mean AIS of the head 3.59 (1.15) 3.94 (0.95) Mean hospital LOS (SD) 5.03 (6.69) 5.12 (3.69) Mean ICU LOS (SD) 2.17 (1.67) 3.09 (2.60) Mean ventilator days (SD) 0.14 (0.74) 0.82 (2.46) Ventilator required 1 (3.5%) 7 (20.6%) Mean initial INR (SD) 3.39 (1.63) 3.41 (2.05) Mean minutes D INR Initial to INR 2nd (SD) (90.7) 412 (381) Mean minutes D INR initial to INR <1.5 (SD) 489 (294) 959 (1192) Mean Units FFP Given (SD) 0.86 (1.09) 3.32 (1.49) <0.001 Mean minutes PCC ordered to PCC given (SD) (36.11) Mean GCS Admit (SD) 14.4 (0.95) 14.3 (2.20) Mean GCS Discharge (SD) 13.4 (3.31) 12.4 (4.48) Mean D GCS (SD) 0.96 (2.94) 1.91 (3.88) Neurosurgical intervention 3 (10.3%) 8 (25.5%) Mortality 2 (6.9%) 5 (14.7%) Extension of intracranial hemorrhage 5 (17.2%) 15 (44.1%) PCC, prothrombin complex concentrate; FFP, fresh-frozen plasma; SD, standard deviation; ISS, Injury Severity Score; AIS, Abbreviated Injury Score; LOS, length of stay; ICU, intensive care unit; INR, international normalized ratio; GCS, Glasgow Coma Scale. neurosurgical intervention (10.3% PCC vs 25.5% control), although they did not reach statistical significance. Discussion In this study we have demonstrated that the use of PCC in a protocolized format is efficacious in decreasing the time for reversal of OAT in head-injured patients, decreasing the amount of FFP needed to reverse OAT, and decreasing the amount of patients that increased the size of their intracranial hemorrhage. There are two types of PCC available for commercial use: three-factor PCC vs four-factor PCC. In the United States, there are currently only two brands of PCCs commercially available (Profilnine SD and Bebulin VH) both of which are three-factor PCC. 23 Europe, Japan, and Australia commonly use fourfactor PCC, which contains significant amounts of anticoagulation factors such as antithrombin, protein C, protein S, and protein Z. 15, 24 Heparin may also be added as well to inhibit activated factors. 15 PCC has been shown to be efficacious in swiftly reversing vitamin K-dependent coagulopathy, whether in the setting of ICH, gastrointestinal bleeding, or to perform an invasive procedure or surgery It may also be used to reverse the anticoagulant effect of the oral factor Xa inhibitor rivaroxaban (Xalreto). 31 PCC has also been used in reversing the bleeding associated with cardiac surgery or other invasive procedures. 32 Others have demonstrated that PCC is effective in the correction of traumatic coagulopathy 33 and dilutional coagulopathy. 34 Kalina et al. 16 showed that a discretionary PCC protocol to treat patients on warfarin sustaining ICH did decrease the time for normalization of INR and time to operative intervention compared to FFP administration but did not show any difference between groups with respect to intensive care unit days, hospital days, or mortality. The PCC that was used in this study (Proplex T) is no longer available in the United States. There are limitations to this study. The sample sizes are small and its retrospective format restricts the interpretation of the data. There was a decrease in the rate intensive care unit length of stay LOS, ventilator use, and total ventilator days, but they did not reach significance, which may be the result of the study being underpowered and therefore represents a Type II error. Further investigation in the differences in neurologic function and outcome between different treatment modalities is crucial. We have shown that PCC is efficacious in rapidly reversing the INR of patients on OAT. It also decreases the amount of FFP used in reversal and therefore may decrease the incidence of transfusion-related acute lung injury 35 and transfusion-associated circulatory overload 36 secondary to FFP. However, FFP may be needed to supplement three-factor PCC, especially for extremely elevated INRs. In addition, patients who received PCC were significantly less likely to experience an increase in the size of the ICH. We believe an urgent protocolized approach to OAT in using PCC has the potential to improve outcome in our geriatric headinjured patient population.
5 376 THE AMERICAN SURGEON April 2014 Vol. 80 REFERENCES US Census data. Available at: gov/faces/tableservices/jsf/pages/productview.xhtml?pid4acs_ 11_1YR_S0103&prodType4table. Accessed October 10, Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg 2001;67: Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma 2002;53: Lavoie A, Ratte S, Clas D, et al. Preinjury warfarin use among elderly patients with closed head injuries in a trauma center. J Trauma 2004;56: Franko J, Kish KJ, O Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006;61: Pieracci FM, Eachempati SR, Shou J, et al. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma 2007;63: McMillian WD, Rogers FB. Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. J Trauma 2009;66: Ivascu FA, Janczyk RJ, Junn FS, et al. Treatment of trauma patients with intracranial hemorrhage on preinjury warfarin. J Trauma 2006;61: Ivascu FA, Howells GA, Junn FS, et al. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma 2005;59: Hanley JP. Warfarin reversal. J Clin Pathol 2004;57: Makris M, Watson HG. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res 2005; 115: Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006;4: Butler AC, Tait RC. Management of oral anticoagulantinduced intracranial haemorrhage. Blood Rev 1998;12: Levy JH, Tanaka KA, Deitrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiolog. 2008;109: Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a prothrombin complex concentrate (OctaplexÒ) for rapid reversal of oral anticoagulation. Thromb Res 2004;113: Kalina M, Tinkoff G, Gbadebo A, et al. A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg 2008;74: Fredriksson K, Norrving B, et al. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23: Rossaint R, Bouillon B, Cerny V, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010;14:R Chong CT, Lew TW, Kuperan P, et al. Rapid reversal of coagulopathy in warfarin-related intracranial hemorrhages with prothrombin complex concentrate. Anaesth Intensive Care 2010; 38: Cabral KP, Fraser GL, Duprey J, et al. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding. Clin Neurol Neurosurg 2013;115: Switzer J, Rocker J, Mohorn P, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke 2012;43: Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother 2011; 45: Dager W. Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects. Ann Pharmacother 2011; 45: Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost 2006;4: Norrving B, Fredriksson K, Strömblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23: Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6: Van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006; 118: Desmettre T, Dubart AE, Capellier G, et al. Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year study from 2006 to Thromb Res 2012;130:e Barillari G, Pasca S, Barillari A, et al. Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. Blood Transfus 2012;10: Riess HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex Ò ) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007;121: Eerebergy ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124: Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008;12:R Joseph B, Amini A, Friese RS, et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma 2012;72: Fuentes GD, Hernandez PJ, Sansano ST, et al. Prothrombin complex concentrate in the treatment of multitransfusional dilutional coagulopathy in a paediatric patient. Br J Anaesth 2011;106: Funk MB, Guenay S, Lohmann A, et al. Benefit of transfusionrelated acute lung injury risk-minimization measures German haemovigilance data ( ). Vox Sang 2012;102: Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52:65S 79S.
6 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC
Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC Ayman Kafal Medical Affairs, Leader CSL Behring Canada 1 Prothrombin Complex
More informationSign up to receive ATOTW weekly -
ANTICOAGULATION & INTRACRANIAL BLEEDS - MANAGEMENT OF THE ANTICOAGULATED PATIENT PRESENTING WITH INTRACRANIAL HAEMORRHAGE ANAESTHESIA TUTORIAL OF THE WEEK 82 12 th January 2008 Rebecca Appelboam, Exeter,
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationDavid Mountain, Vera Sistenich and Ian G Jacobs
Characteristics, management and outcomes of adults with major trauma taking pre-injury warfarin in a Western Australian population from 2000 to 2005: a population-based cohort study David Mountain, Vera
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationPurpose. Page 2 of 11
Medical Imaging in Emergency Medicine: Assessing the Use of Serial Imaging to Screen for Delayed Intracranial Haemorrhage in Patients on Anticoagulant and Antiplatelet Therapy Poster No.: R-0143 Congress:
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationORIGINAL ARTICLE. Prevalence and Implications of Preinjury Warfarin Use
ONLINE FIRST ORIGINAL ARTICLE Prevalence and Implications of Preinjury Warfarin Use An Analysis of the National Trauma Databank Lesly A. Dossett, MD, MPH; Johanna N. Riesel, MD; Marie R. Griffin, MD, MPH;
More information5/15/2018. Reduced Platelet Activity
ASSOCIATION OF DESMOPRESSIN ACETATE ON OUTCOMES IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS ON ANTIPLATELET THERAPY Jessica McManus, Pharm. D. PGY2 Critical Care Pharmacy Resident UF Health Jacksonville
More informationUse of Anticoagulant Reversal Agents
Use of Anticoagulant Reversal Agents Lori Shutter, MD shutterla@upmc.edu Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)
Approved by NPPEAG 18 December 2018 Reviewed 18 December 2018 To be reviewed 18 December 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Protocol for the Reversal
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationWARFARIN REVERSAL GUIDELINE
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationExcessive anticoagulation identified by emergency medical service through point-of-care coagulometry
Excessive anticoagulation identified by emergency medical service through point-of-care coagulometry BY CHRISTOPHER BEYNON, ANGELINA G ERK, STEFAN MOHR, FELIX HEISER, ERIK POPP Abstract Bleeding because
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationFinancial Disclosure. Objectives 9/24/2018
Hemorrhage and Transfusion Adjuncts in the Setting of Damage Control Joseph Cuschieri, MD FACS Professor of Surgery, University of Washington Adjunct Professor of Orthopedics and Neurosurgery, University
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationStudy title: Safety of therapeutic anticoagulation in patients with traumatic brain injury: a multicenter prospective observational study
Study title: Safety of therapeutic anticoagulation in patients with traumatic brain injury: a multicenter prospective observational study Primary investigator: Kazuhide Matsushima, MD Email: kazuhide.matsushima@med.usc.edu
More informationManagement of the Elderly Anti-coagulated Trauma Patient. Dr Paul Bradford ER Physician, Trauma Team Leader Hotel Dieu Hospital Windsor
Management of the Elderly Anti-coagulated Trauma Patient Dr Paul Bradford ER Physician, Trauma Team Leader Hotel Dieu Hospital Windsor Geriatric Trauma Issues 5 th leading cause of death Higher mortality,
More informationOutcomes of Urgent Warfarin Reversal Using Fresh Frozen Plasma versus. Prothrombin Complex Concentrate in the Emergency Department
Outcomes of Urgent Warfarin Reversal Using Fresh Frozen Plasma versus Prothrombin Complex Concentrate in the Emergency Department Running title: Hickey et al.; Complications from Octaplex versus FFP Michael
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationPosition statement: Anti-coagulants and Risk Assessment
Position statement: Anti-coagulants and Risk Assessment Document information Protective marking: NOT PROTECTVELY MARKED Author: Matt Johnston Force/Organisation: College of Policing NPCC Coordination Committee
More informationGUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN
GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN Version Date Purpose of Issue/Description of Change Review Date 1 29/11/05 New Policy December 2007 2 Oct 07 Review Oct 09 3 March 10 Review
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationIncidence and Impact of Antithrombotic-related Intracerebral Hemorrhage
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage John J. Lewin III, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS Division Director, Critical Care & Surgery Pharmacy Services, The Johns
More information10/1/2013. I have no actual or potential conflict of interest with today s presentation
I have no actual or potential conflict of interest with today s presentation Kimberly C. Berger, PharmD, BCPS Clinical Specialist Critical Care Rush University Medical Center October 2, 2013 Review the
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationRobert Moesinger MD--Moderator Joe Hansler MD--Surgery Justin Mansfield MD Internal Medicine Charles Ivester MD, PHD Pulmonology/Critical Care John
Robert Moesinger MD--Moderator Joe Hansler MD--Surgery Justin Mansfield MD Internal Medicine Charles Ivester MD, PHD Pulmonology/Critical Care John Lund MD--Cardiology This presentation has no commercial
More informationICU. Recovery. Plus Ultrasound-guided mechanical ventilation, F. Mojoli & S. Mongodi MANAGEMENT & PRACTICE
ICU MANAGEMENT & PRACTICE VOLUME 17 - ISSUE 3 - AUTUMN 2017 CSL Behring Supplement from Euroanaesthesia 2017 Symposium Recovery The role of autophagy in the metabolism and outcomes after surgery, J. Gunst
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationKcentra Formulary Kit
Formulary Kit The first and only 4F-PCC for urgent warfarin reversal Important Safety Information is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationEmergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies
AACN Advanced Critical Care Volume 25, Number 1, pp. 5-12 2014 AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Emergent Reversal of Oral Anticoagulation:
More informationInnovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS
Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis Prof. Ralf R.Kolvenbach MD,PhD,FEBVS Catheter-based thrombolysis Local administration of lytic agent Higher local
More informationEAST MULTICENTER STUDY DATA DICTIONARY
EAST MULTICENTER STUDY DATA DICTIONARY Does the Addition of Daily Aspirin to Standard Deep Venous Thrombosis Prophylaxis Reduce the Rate of Venous Thromboembolic Events? Data Entry Points and appropriate
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationWarfarin is an oral anticoagulant that is used to
J Neurosurg 119:1050 1057, 2013 AANS, 2013 Mild elevations of international normalized ratio at hospital Day 1 and risk of expansion in warfarin-associated subdural hematomas Clinical article Marie Roguski,
More informationReview of the TICH-2 Trial
Review of the TICH-2 Trial Mikaela Hofer, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds September 18, 2018 2018 MFMER slide-1 Objectives Review the pharmacologic options to limit hematoma expansion
More informationEverything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science
Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationHigh Risk + Challenging Trauma Cases. Hawaii. Topics 1/27/2014. David Thompson, MD, MPH. Head injury in the anticoagulated patient.
High Risk + Challenging Trauma Cases David Thompson, MD, MPH Hawaii Topics Head injury in the anticoagulated patient Shock recognition Case 1: Head injury HPI: 57 yo male w/ PMH atrial fibrillation, on
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationHow Low Should You Go? Management of Blood Pressure in Intracranial Hemorrhage
How Low Should You Go? Management of Blood Pressure in Intracranial Hemorrhage Rachael Scott, Pharm.D. PGY2 Critical Care Pharmacy Resident Pharmacy Grand Rounds August 21, 2018 2018 MFMER slide-1 Patient
More informationGUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS
GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationRESULT SUMMARY BE1116_3001. Acquired deficiency of prothrombin complex (reversal of oral anticoagulation)
RESULT SUMMARY Efficacy and tolerance of BERIPLEX P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation BE1116_3001 Investigational product: Beriplex
More informationAnticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics
MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More informationHit head, on blood thinner-wife wants CT. Will Davies June 2014
Hit head, on blood thinner-wife wants CT Will Davies June 2014 Selection of Adults with Head Injury for CT Scan Early management of head injury: summary of updated NICE guidance. Hodgkinson S, Pollit V,
More informationOral anticoagulant agent-associated bleeding events reporting system (ORANGE study)
Oral anticoagulant agent-associated bleeding events reporting system (ORANGE study) Laura Green 1,2,3, Joan Morris 1, Raza Alikhan 4, Nicola Curry 5, Rhona Maclean 6, Khalid Saja 7, Simon Stanworth 3,5,
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationEffect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate
PHARMACY MANAGEMENT AJHP RESIDENTS EDITION Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate Eileen Langstraat, Pharm.D., BCPS, Department of Pharmacy, Kaiser
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationGeriatric Trauma Resuscitation: Lessons from a Geriatric Trauma Surgeon
Geriatric Trauma Resuscitation: Lessons from a Geriatric Trauma Surgeon Aurelio Rodriguez, M.D., FACS Conemaugh Memorial Medical Center Trauma Center Johnstown, PA Demographics The fastest growing age
More informationControversies in Hemorrhagic Stroke Management. Sarah L. Livesay, DNP, RN, ACNP-BC, ACNS-BC Associate Professor Rush University
Controversies in Hemorrhagic Stroke Management Sarah L. Livesay, DNP, RN, ACNP-BC, ACNS-BC Associate Professor Rush University Disclosures AHA/ASA Outline Blood pressure VTE Coagulopathy Early mobilization
More informationEAST MULTICENTER STUDY DATA DICTIONARY. Temporary Intravascular Shunt Study Data Dictionary
EAST MULTICENTER STUDY DATA DICTIONARY Temporary Intravascular Shunt Study Data Dictionary Data Entry Points and appropriate definitions / clarifications: Entry space Definition / Instructions 1. Specific
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationUnder Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare
Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian Barry McKenzie, MD St. Vincent Healthcare Objectives Describe the increasing frequency of trauma patients being
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: In: By: For: Key words: Written by: All Clinical Areas All medical and nursing staff Adult patients requiring anticoagulation with warfarin
More informationThis quiz is being published on behalf of the Education Committee of the SNACC.
Shobana Rajan, M.D. Staff Anesthesiologist, Cleveland Clinic, Cleveland, Ohio Quiz team; Shaheen Shaikh, M.D; Suneeta Gollapudy,M.D; Verghese Cherian, M.D This quiz is being published on behalf of the
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital
ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity
More informationThe Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
Wood et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine (2017) 25:76 DOI 10.1186/s13049-017-0420-y ORIGINAL RESEARCH The Anticoagulated trauma patient in the age of the direct
More informationManagement of the Trauma Patient. Elizabeth R Benjamin MD PhD Trauma and Surgical Critical Care Critical Care Symposium April 20, 2015
Management of the Trauma Patient Elizabeth R Benjamin MD PhD Trauma and Surgical Critical Care Critical Care Symposium April 20, 2015 Saturday Night 25 yo M s/p high speed MVC Hypotensive in the ED, altered
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationUniversity of Groningen
University of Groningen Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist- Related Intracranial Hemorrhage Abdoellakhan, Rahat; Miah, Ishita Parveen; Khorsand, Nakisa;
More informationEVIDENCE ON MINOR HEAD INJURY IN GERIATRICS. Janet Talbot-Stern, FACEM, FRCEM, FACEP
EVIDENCE ON MINOR HEAD INJURY IN GERIATRICS Janet Talbot-Stern, FACEM, FRCEM, FACEP Definition: Minor head injury 1 Minor HI GCS 15, LOC, amnesia or confusion Minimal HI GCS 15, no LOC, amnesia or confusion
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationThe research questions are presented in priority order, and are further elaborated with lay summaries and three-part questions where applicable.
Top 30 Emergency Medicine Research Priorities 23 January 2017 The rankings were established by consensus at the final prioritisation workshop run by the James Lind Alliance Emergency Medicine Priority
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPrimary Stroke Center Quality & Performance Measures
Primary Stroke Center Quality & Performance Measures This section of the manual contains information related to the quality performance of Primary Stroke Centers. Brain Attack Coalition Definitions Recognition
More informationGoals. Geriatric Trauma. What s the impact Erlanger Trauma Symposium
Geriatric Trauma William S. Havron III MD Assistant Professor of Surgery University of Oklahoma Goals Realize the impact of injuries in the ageing population Identify the pitfalls associated with geriatric
More informationResuscitation Update
Resuscitation Update? Dr. Edward Pyun Jr., M.D. FACS Trauma Medical Director/Surgical ICU Director OSF St. Anthony Medical Center Trauma Services Perryville Surgical Associates November 10, 2012 2009 Recommendations
More information